Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q5JTZ9

UPID:
SYAM_HUMAN

ALTERNATIVE NAMES:
Alanyl-tRNA synthetase

ALTERNATIVE UPACC:
Q5JTZ9; A2RRN5; Q8N198; Q96D02; Q9ULF0

BACKGROUND:
The mitochondrial enzyme Alanine--tRNA ligase, known alternatively as Alanyl-tRNA synthetase, is essential for protein biosynthesis. It activates alanine and attaches it to tRNA(Ala), a critical step for the accurate assembly of proteins. Its unique editing capability also prevents errors in protein synthesis by correcting mischarged tRNA(Ala).

THERAPEUTIC SIGNIFICANCE:
Alanine--tRNA ligase, mitochondrial, is linked to severe genetic disorders, including Combined oxidative phosphorylation deficiency 8 and progressive Leukoencephalopathy with ovarian failure. Exploring the function of this protein offers a promising pathway to novel treatments for these debilitating diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.